Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+breast cancer (BC): A network meta-analysis (NMA).

被引：1
|
作者：
Pelizzari, Giacomo
Gerratana, Lorenzo
Basile, Debora
Bartoletti, Michele
Lisanti, Camilla
Garattini, Silvio Ken
Bortot, Lucia
Corvaja, Carla
Buriolla, Silvia
Curtolo, Gianluca
Garutti, Mattia
Di Nardo, Paola
Torrisi, Elena
Da Ros, Lucia
Freschi, Andrea
Saracchini, Silvana
Bolzonello, Silvia
Miolo, Gianmaria
Spazzapan, Simon
Puglisi, Fabio
机构：
[1] Univ Udine, Dept Med DAME, Udine, Italy
[2] IRCCS, Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Med, Udine, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, UOC Oncol, Rome, Italy
[4] IRCCS, Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Med, Rome, Italy
[5] IRCCS, Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Med, Aviano, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.577
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
577
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of anthracyclines in neoadjuvant therapy in HER2+breast cancer. A systematic review and network meta-analysis (NMA)
    Villacampa Javierre, G.
    Pascual, T.
    Matikas, A.
    Papakonstantinou, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S604 - S604
  • [2] Efficacy and safety of anti-HER2 therapy in neoadjuvant therapy for HER2positive breast cancer: a network meta-analysis
    Gan, Lu
    Li, Fangxuan
    Su, Jialin
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Dual HER2 Blockade in Neoadjuvant Treatment of HER2+Breast Cancer: A Meta-Analysis and Review
    Wang, Chaokun
    Chen, Jing
    Xu, Xiangyun
    Hu, Xiaochen
    Kong, Dejiu
    Liang, Gaofeng
    Wang, Xinshuai
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [4] Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+breast cancer
    Gagliato, Debora de Melo
    Fontes Jardim, Denis Leonardo
    Pereira Marchesi, Mario Sergio
    Hortobagyi, Gabriel N.
    ONCOTARGET, 2016, 7 (39) : 64431 - 64446
  • [5] The optimal neoadjuvant treatment regimen for HR+/HER2+breast cancer: a network meta-analysis
    Wang, Hao
    Liu, Shiwei
    Yu, Miao
    Mi, Kun
    Mou, Exian
    Xia, Li
    Xie, Weimin
    Tang, Hao
    Feng, Yajing
    Yu, Xin
    CANCER RESEARCH, 2024, 84 (09)
  • [6] The optimal neoadjuvant treatment strategy for HR+/HER2+breast cancer: a network meta-analysis
    Liu, Shiwei
    Yu, Miao
    Mou, Exian
    Wang, Meihua
    Liu, Shuanghua
    Xia, Li
    Li, Hui
    Tang, Hao
    Feng, Yajing
    Yu, Xin
    Mi, Kun
    Wang, Hao
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [7] Mevalonate pathway mediates acquired anti-HER2 treatment resistance in HER2+breast cancer
    Hu, Huizhong
    Simon, Lukas
    Qin, Lanfang
    Nardone, Agostina
    Shaw, Chad
    Chamness, Gary
    Heiser, Laura
    Wang, Nicholas
    Gray, Joe W.
    Osborne, C. Kent
    Schiff, Rachel
    CANCER RESEARCH, 2015, 75
  • [8] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [9] Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis
    Debiasi, Marcio
    Polanczyk, Carisi A.
    Ziegelmann, Patricia
    Barrios, Carlos
    Cao, Hongyuan
    Dignam, James J.
    Goss, Paul
    Bychkovsky, Brittany
    Finkelstein, Dianne M.
    Guindalini, Rodrigo S.
    Filho, Paulo
    Albuquerque, Caroline
    Reinert, Tomas
    de Azambuja, Evandro
    Olopade, Olufunmilayo
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [10] Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+Breast Cancer: Real-World Evidence
    de Pinho, Ines Soares
    Luz, Paulo
    Alves, Lucy
    Lopes-Bras, Raquel
    Patel, Vanessa
    Esperanca-Martins, Miguel
    Goncalves, Lisa
    Freitas, Ritas
    Simao, Diana
    Galnares, Maria Roldan
    Fernandes, Isabel
    Criado, Silvia Artacho
    Casado, Salvador Gamez
    Canada, Jose Baena
    Vega, Isabel M. Saffie
    Costa, Joao G.
    Fernandes, Ana S.
    de Sousa, Rita Teixeira
    Costa, Luis
    CLINICAL DRUG INVESTIGATION, 2023, 43 (09) : 691 - 698
12345